Q’Apel Medical marketed an uncleared modified HIPPO stroke aspiration device and had quality system violations, FDA says.
What happened
FDA inspected Q’Apel Medical in Fremont, CA from July 29 to August 8, 2024. FDA reviewed inspection information and promotion—including tip compression test data and videos—and said the HIPPO device marketed has a nitinol tip that expands in diameter and compresses in length, features not described in cleared submission K222786. FDA also cited quality system violations in design input, design verification, design change, complaint handling, and document control.
What FDA found
FDA says Q’Apel marketed a HIPPO with a nitinol tip that expands and compresses, features not described in the cleared submission, without the FDA approval, study permission, or premarket notification required for the device as marketed.
section 501(f)(1)(B), 21 U.S.C. §351(f)(1)(B); section 502(o), 21 U.S.C. §352(o); section 510(k), 21 U.S.C. §360(k)FDA says Q’Apel did not adequately document the physical and performance requirements it used as design inputs for tip compression, suction pump, tip deflection, and treatment location.
21 CFR 820.30(c)FDA says Q’Apel did not set pass/fail limits that could be verified for aspiration flow rate, tip deflection, and tip compression/elongation, and did not justify testing only one suction setting.
21 CFR 820.30(f)FDA says Q’Apel made design changes without documenting whether they affected completed verification and validation tests, or why tests were not needed.
21 CFR 820.30(i)FDA says Q’Apel did not investigate returned complaint products within its 30-day procedure for two complaints received in June 2024.
21 CFR 820.198(a)FDA says promotional materials for HIPPO—including videos showing tip flaring and a press release calling the tip adaptive—were not developed and approved under its document control procedures.
21 CFR 820.40
What FDA wants
FDA asks Q’Apel to stop activities that cause misbranding or adulteration, such as commercial distribution for the uses discussed, and to reply in writing within 15 business days with corrective actions, documentation, and a plan to prevent recurrence.
Who should pay attention
- hospital stroke teams that use or stock aspiration catheters
- distributors and buyers of Q’Apel HIPPO devices
- makers of nitinol-tip neurovascular catheters
This is a summary. Read the original letter on fda.gov.